Department of Applied and Human Sciences
Kingston upon Thames, KT1 2EE, United Kingdom
NCT Number: NCT07611877
The goal of this clinical trial (randomised, double-blind, placebo-controlled crossover study) is to investigate whether supplementation with Ecklonia cava, a natural extract derived from brown seaweed, affects exercise performance and physiological responses in trained cyclists.
The main questions it aims to answer are:
Does Ecklonia cava supplementation improve cycling performance, including power output during steady-state exercise and short maximal sprints? Does Ecklonia cava supplementation influence physiological responses to exercise, such as blood glucose, blood lactate, heart rate, and oxygen consumption?
Researchers will compare Ecklonia cava supplementation to a placebo (a look-alike substance with no active ingredients) to determine whether the supplement has any effect on performance or physiological responses.
In this crossover design, all participants will receive both the Ecklonia cava supplement and the placebo on separate occasions, with a washout period between conditions.
Participants will:
Ingest either Ecklonia cava or a placebo 30 minutes before exercise testing Complete a 60-minute cycling protocol at a moderate intensity Perform repeated short-duration maximal sprint efforts following the steady-state exercise Attend laboratory testing sessions under both supplement and placebo conditions Undergo measurements of physiological responses, including blood glucose, blood lactate, heart rate, oxygen consumption, and respiratory exchange ratio Have exercise performance assessed through measures of power output during cycling
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
Kingston upon Thames, KT1 2EE, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Placebo Supplementation
Ecklonia Cava Supplementation
Time frame: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Peak power output achieved during 20-second maximal sprint efforts performed following a fixed-intensity (55% Wmax) 60-minute cycling protocol
Time frame: Immediately after the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Mean power output recorded during repeated 20-second maximal sprint efforts following steady-state cycling
Time frame: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Blood lactate concentration measured following each repeated sprint efforts (3)
Time frame: Repeated sprint cycling (3) completed immediately after the 60-minute submaximal cycling protocol, a blood sample taken 2 minutes after each sprint cycling bout. Following each 30-minute supplementation protocol.
Blood glucose concentration measured following repeated sprint efforts
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation (each condition)
Average heart rate measured during a 60-minute steady-state cycling protocol performed at 55% maximal power output
Time frame: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Blood lactate concentration measured during steady-state cycling at 55% maximal power output
Time frame: Every 20-minutes during the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Blood glucose concentration measured during steady-state cycling at 55% maximal power output
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Oxygen consumption measured using indirect calorimetry during steady-state cycling
Time frame: During the 60-minute submaximal cycling protocol, 30 minutes after supplementation
Respiratory exchange ratio measured during steady-state cycling using expired gas analysis
University of Exeter
Other
Acute Ecklonia Cava Supplementation Fails to Enhance Performance in Trained Cyclists
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00972387
Supplementation During Endurance Performance
Knoxville, Tennessee, United States
View Trial DetailsNCT07341789
Behavior, Behavioral Symptoms
La Ñora, Murcia, Spain
View Trial Details